AT 2.25 MG/m2 IV WEEKLY
COMPLETE REMISSION RATE 4.6%
WITH OF COURSE NEUROPATHY IN ALMOST 40% OF PATIENTS
BUT EFFECTIVE EVEN WITHOUT ASPARAGINASE
Liposomal encapsulation prolongs its presence in the blood and ability to penetrate the marrow, lymph nodes and spleen).
------------------------------------------------------------------
Jakafi, for your Myelofibrosis patient with positive JAK2V617F positive and negative patient
with a 35% reduction in splenomegaly at 24 weeks occurring in 41% of patients.
will check out the JAK signaling!
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment